Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator (original) (raw)

Abstract

The availability of gene-targeted mice deficient in the urokinase-type plasminogen activator (uPA), urokinase receptor (uPAR), tissue-type plasminogen activator (tPA), and plasminogen permits a critical, genetic-based analysis of the physiological and pathological roles of the two mammalian plasminogen activators. We report a comparative study of animals with individual and combined deficits in uPAR and tPA and show that these proteins are complementary fibrinolytic factors in mice. Sinusoidal fibrin deposits are found within the livers of nearly all adult mice examined with a dual deficiency in uPAR and tPA, whereas fibrin deposits are never found in livers collected from animals lacking uPAR and rarely detected in animals lacking tPA alone. This is the first demonstration that uPAR has a physiological role in fibrinolysis. However, uPAR-/-/tPA-/- mice do not develop the pervasive, multi-organ fibrin deposits, severe tissue damage, reduced fertility, and high morbidity and mortality observed in mice with a combined deficiency in tPA and the uPAR ligand, uPA. Furthermore, uPAR-/-/tPA-/- mice do not exhibit the profound impairment in wound repair seen in uPA-/-/tPA-/- mice when they are challenged with a full-thickness skin incision. These results indicate that plasminogen activation focused at the cell surface by uPAR is important in fibrin surveillance in the liver, but that uPA supplies sufficient fibrinolytic potential to clear fibrin deposits from most tissues and support wound healing without the benefit of either uPAR or tPA.

5899

Images in this article

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Altieri D. C., Plescia J., Plow E. F. The structural motif glycine 190-valine 202 of the fibrinogen gamma chain interacts with CD11b/CD18 integrin (alpha M beta 2, Mac-1) and promotes leukocyte adhesion. J Biol Chem. 1993 Jan 25;268(3):1847–1853. [PubMed] [Google Scholar]
  2. Beck E., Ludwig G., Auerswald E. A., Reiss B., Schaller H. Nucleotide sequence and exact localization of the neomycin phosphotransferase gene from transposon Tn5. Gene. 1982 Oct;19(3):327–336. doi: 10.1016/0378-1119(82)90023-3. [DOI] [PubMed] [Google Scholar]
  3. Bini A., Kudryk B. J. Fibrin and its derivatives in the normal and diseased vessel wall. Ann N Y Acad Sci. 1992 Dec 4;667:112–126. doi: 10.1111/j.1749-6632.1992.tb51604.x. [DOI] [PubMed] [Google Scholar]
  4. Blasi F., Vassalli J. D., Danø K. Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors. J Cell Biol. 1987 Apr;104(4):801–804. doi: 10.1083/jcb.104.4.801. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bugge T. H., Flick M. J., Daugherty C. C., Degen J. L. Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Dev. 1995 Apr 1;9(7):794–807. doi: 10.1101/gad.9.7.794. [DOI] [PubMed] [Google Scholar]
  6. Bugge T. H., Suh T. T., Flick M. J., Daugherty C. C., Rømer J., Solberg H., Ellis V., Danø K., Degen J. L. The receptor for urokinase-type plasminogen activator is not essential for mouse development or fertility. J Biol Chem. 1995 Jul 14;270(28):16886–16894. doi: 10.1074/jbc.270.28.16886. [DOI] [PubMed] [Google Scholar]
  7. Carmeliet P., Schoonjans L., Kieckens L., Ream B., Degen J., Bronson R., De Vos R., van den Oord J. J., Collen D., Mulligan R. C. Physiological consequences of loss of plasminogen activator gene function in mice. Nature. 1994 Mar 31;368(6470):419–424. doi: 10.1038/368419a0. [DOI] [PubMed] [Google Scholar]
  8. Crowley C. W., Cohen R. L., Lucas B. K., Liu G., Shuman M. A., Levinson A. D. Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):5021–5025. doi: 10.1073/pnas.90.11.5021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Danø K., Andreasen P. A., Grøndahl-Hansen J., Kristensen P., Nielsen L. S., Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res. 1985;44:139–266. doi: 10.1016/s0065-230x(08)60028-7. [DOI] [PubMed] [Google Scholar]
  10. Dewerchin M., Nuffelen A. V., Wallays G., Bouché A., Moons L., Carmeliet P., Mulligan R. C., Collen D. Generation and characterization of urokinase receptor-deficient mice. J Clin Invest. 1996 Feb 1;97(3):870–878. doi: 10.1172/JCI118489. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Dvorak H. F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med. 1986 Dec 25;315(26):1650–1659. doi: 10.1056/NEJM198612253152606. [DOI] [PubMed] [Google Scholar]
  12. Estreicher A., Mühlhauser J., Carpentier J. L., Orci L., Vassalli J. D. The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J Cell Biol. 1990 Aug;111(2):783–792. doi: 10.1083/jcb.111.2.783. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Grainger D. J., Kemp P. R., Liu A. C., Lawn R. M., Metcalfe J. C. Activation of transforming growth factor-beta is inhibited in transgenic apolipoprotein(a) mice. Nature. 1994 Aug 11;370(6489):460–462. doi: 10.1038/370460a0. [DOI] [PubMed] [Google Scholar]
  14. Guy C. T., Cardiff R. D., Muller W. J. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol. 1992 Mar;12(3):954–961. doi: 10.1128/mcb.12.3.954. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. HE C. S., Wilhelm S. M., Pentland A. P., Marmer B. L., Grant G. A., Eisen A. Z., Goldberg G. I. Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc Natl Acad Sci U S A. 1989 Apr;86(8):2632–2636. doi: 10.1073/pnas.86.8.2632. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Kramer M. D., Schaefer B., Reinartz J. Plasminogen activation by human keratinocytes: molecular pathways and cell-biological consequences. Biol Chem Hoppe Seyler. 1995 Mar;376(3):131–141. doi: 10.1515/bchm3.1995.376.3.131. [DOI] [PubMed] [Google Scholar]
  17. Kristensen P., Eriksen J., Danø K. Localization of urokinase-type plasminogen activator messenger RNA in the normal mouse by in situ hybridization. J Histochem Cytochem. 1991 Mar;39(3):341–349. doi: 10.1177/39.3.1899685. [DOI] [PubMed] [Google Scholar]
  18. Larsson L. I., Skriver L., Nielsen L. S., Grøndahl-Hansen J., Kristensen P., Danø K. Distribution of urokinase-type plasminogen activator immunoreactivity in the mouse. J Cell Biol. 1984 Mar;98(3):894–903. doi: 10.1083/jcb.98.3.894. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Lupu F., Heim D. A., Bachmann F., Hurni M., Kakkar V. V., Kruithof E. K. Plasminogen activator expression in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 1995 Sep;15(9):1444–1455. doi: 10.1161/01.atv.15.9.1444. [DOI] [PubMed] [Google Scholar]
  20. Mars W. M., Liu M. L., Kitson R. P., Goldfarb R. H., Gabauer M. K., Michalopoulos G. K. Immediate early detection of urokinase receptor after partial hepatectomy and its implications for initiation of liver regeneration. Hepatology. 1995 Jun;21(6):1695–1701. [PubMed] [Google Scholar]
  21. Odekon L. E., Blasi F., Rifkin D. B. Requirement for receptor-bound urokinase in plasmin-dependent cellular conversion of latent TGF-beta to TGF-beta. J Cell Physiol. 1994 Mar;158(3):398–407. doi: 10.1002/jcp.1041580303. [DOI] [PubMed] [Google Scholar]
  22. Ossowski L., Clunie G., Masucci M. T., Blasi F. In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion. J Cell Biol. 1991 Nov;115(4):1107–1112. doi: 10.1083/jcb.115.4.1107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Ossowski L., Russo-Payne H., Wilson E. L. Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse. Cancer Res. 1991 Jan 1;51(1):274–281. [PubMed] [Google Scholar]
  24. Ploplis V. A., Carmeliet P., Vazirzadeh S., Van Vlaenderen I., Moons L., Plow E. F., Collen D. Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice. Circulation. 1995 Nov 1;92(9):2585–2593. doi: 10.1161/01.cir.92.9.2585. [DOI] [PubMed] [Google Scholar]
  25. Ploug M., Plesner T., Rønne E., Ellis V., Høyer-Hansen G., Hansen N. E., Danø K. The receptor for urokinase-type plasminogen activator is deficient on peripheral blood leukocytes in patients with paroxysmal nocturnal hemoglobinuria. Blood. 1992 Mar 15;79(6):1447–1455. [PubMed] [Google Scholar]
  26. Plump A. S., Smith J. D., Hayek T., Aalto-Setälä K., Walsh A., Verstuyft J. G., Rubin E. M., Breslow J. L. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 1992 Oct 16;71(2):343–353. doi: 10.1016/0092-8674(92)90362-g. [DOI] [PubMed] [Google Scholar]
  27. Rickles R. J., Darrow A. L., Strickland S. Molecular cloning of complementary DNA to mouse tissue plasminogen activator mRNA and its expression during F9 teratocarcinoma cell differentiation. J Biol Chem. 1988 Jan 25;263(3):1563–1569. [PubMed] [Google Scholar]
  28. Rickles R. J., Strickland S. Tissue plasminogen activator mRNA in murine tissues. FEBS Lett. 1988 Feb 29;229(1):100–106. doi: 10.1016/0014-5793(88)80806-8. [DOI] [PubMed] [Google Scholar]
  29. Romer J., Bugge T. H., Pyke C., Lund L. R., Flick M. J., Degen J. L., Dano K. Impaired wound healing in mice with a disrupted plasminogen gene. Nat Med. 1996 Mar;2(3):287–292. doi: 10.1038/nm0396-287. [DOI] [PubMed] [Google Scholar]
  30. Ross R. Cell biology of atherosclerosis. Annu Rev Physiol. 1995;57:791–804. doi: 10.1146/annurev.ph.57.030195.004043. [DOI] [PubMed] [Google Scholar]
  31. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993 Apr 29;362(6423):801–809. doi: 10.1038/362801a0. [DOI] [PubMed] [Google Scholar]
  32. Rotoli B., Luzzatto L. Paroxysmal nocturnal hemoglobinuria. Semin Hematol. 1989 Jul;26(3):201–207. [PubMed] [Google Scholar]
  33. Rømer J., Lund L. R., Eriksen J., Pyke C., Kristensen P., Danø K. The receptor for urokinase-type plasminogen activator is expressed by keratinocytes at the leading edge during re-epithelialization of mouse skin wounds. J Invest Dermatol. 1994 Apr;102(4):519–522. doi: 10.1111/1523-1747.ep12373187. [DOI] [PubMed] [Google Scholar]
  34. Rømer J., Lund L. R., Eriksen J., Ralfkiaer E., Zeheb R., Gelehrter T. D., Danø K., Kristensen P. Differential expression of urokinase-type plasminogen activator and its type-1 inhibitor during healing of mouse skin wounds. J Invest Dermatol. 1991 Nov;97(5):803–811. doi: 10.1111/1523-1747.ep12486833. [DOI] [PubMed] [Google Scholar]
  35. Simon D. I., Ezratty A. M., Francis S. A., Rennke H., Loscalzo J. Fibrin(ogen) is internalized and degraded by activated human monocytoid cells via Mac-1 (CD11b/CD18): a nonplasmin fibrinolytic pathway. Blood. 1993 Oct 15;82(8):2414–2422. [PubMed] [Google Scholar]
  36. Smith E. B., Thompson W. D. Fibrin as a factor in atherogenesis. Thromb Res. 1994 Jan 1;73(1):1–19. doi: 10.1016/0049-3848(94)90049-3. [DOI] [PubMed] [Google Scholar]
  37. Solberg H., Løber D., Eriksen J., Ploug M., Rønne E., Behrendt N., Danø K., Høyer-Hansen G. Identification and characterization of the murine cell surface receptor for the urokinase-type plasminogen activator. Eur J Biochem. 1992 Apr 15;205(2):451–458. doi: 10.1111/j.1432-1033.1992.tb16799.x. [DOI] [PubMed] [Google Scholar]
  38. Suh T. T., Holmbäck K., Jensen N. J., Daugherty C. C., Small K., Simon D. I., Potter S., Degen J. L. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. Genes Dev. 1995 Aug 15;9(16):2020–2033. doi: 10.1101/gad.9.16.2020. [DOI] [PubMed] [Google Scholar]
  39. Unkeless J. C., Gordon S., Reich E. Secretion of plasminogen activator by stimulated macrophages. J Exp Med. 1974 Apr 1;139(4):834–850. doi: 10.1084/jem.139.4.834. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Vassalli J. D., Hamilton J., Reich E. Macrophage plasminogen activator: induction by concanavalin A and phorbol myristate acetate. Cell. 1977 Jul;11(3):695–705. doi: 10.1016/0092-8674(77)90086-1. [DOI] [PubMed] [Google Scholar]
  41. Vassalli J. D., Wohlwend A., Belin D. Urokinase-catalyzed plasminogen activation at the monocyte/macrophage cell surface: a localized and regulated proteolytic system. Curr Top Microbiol Immunol. 1992;181:65–86. doi: 10.1007/978-3-642-77377-8_3. [DOI] [PubMed] [Google Scholar]